stockrow
Friday 6 November 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024.
- Revenue
- +29.9%
- EPS
- −49.9%
- Free cash flow
- −19.7%
- Total debt
- +1.29%
Quarter to September 2026, against a year earlier
26.65
0.64
+2.46%
Follow CBLL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — |
+8 more TTM periods Free account |
| (52.47%) | (43.93%) | (37.53%) | (30.83%) | ||
| (41.52%) | (35.29%) | (30.84%) | (25.36%) | ||
ROIC |
(236.27%) | (229.76%) | (207.65%) | (229.77%) | |
Return on Tangible Assets |
(56.32%) | (46.34%) | (39.04%) | (31.50%) | |
Average Days of Receivables |
59.73 | 57.26 | 60.33 | 61.69 | |
Free Cash Flow per Share |
(1.52) | (1.47) | (1.35) | (1.16) | |
Free Cash Flow |
(58.37) | (56.10) | (50.77) | (42.33) | |
Capital Expenditures |
(2.36) | (2.06) | (2.07) | (1.52) | |
| Other line items | |||||
Cash ROIC |
(22.89%) | (20.21%) | (16.82%) | (12.66%) | |
Accounts Receivable Turnover |
7.24 | 7.20 | 7.04 | 6.87 | |
Accounts Payable Turnover |
5.17 | 4.02 | 6.97 | 5.42 | |
Inventory Turnover |
1.80 | 1.78 | 1.74 | 1.52 | |
Average Days of Payables |
72.98 | 102.71 | 61.92 | 96.01 | |
Days of Inventory on Hand |
217.47 | 217.25 | 215.74 | 246.56 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
23.34% | 22.51% | 22.15% | 21.49% | |
Selling, General and Administrative Expense of Revenue |
135.71% | 135.01% | 133.88% | 131.97% | |
Share Based Compensation of Revenue |
18.56% | 16.11% | 14.30% | 13.72% | |
Interest Coverage |
(47.39) | (38.57) | (35.05) | (30.90) | |
Operating CF/Net income |
0.76 | 0.82 | 0.81 | 0.76 | |
Depreciation/Fixed assets |
(0.48) | (0.71) | (0.52) | (0.13) | |
Capex/Depreciation |
2.77 | 1.66 | 2.08 | 5.97 | |
Revenue per Share |
2.82 | 2.68 | 2.52 | 2.44 | |
Operating CF per Share |
(1.45) | (1.42) | (1.29) | (1.12) | |
Capex per Share |
(0.06) | (0.05) | (0.05) | (0.04) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026